Lexaria Bioscience Announces $2 Million Stock Offering to Support Drug Delivery Technology Development

Lexaria Bioscience Corp. has announced a registered direct offering of 2 million shares of common stock at $1.00 per share, generating gross proceeds of $2 million for the company. This financial transaction is scheduled to close around April 28, 2025, subject to standard closing conditions being met. The company has engaged H.C. Wainwright & Co. as the exclusive placement agent for this capital-raising initiative, ensuring professional execution of the offering process.

The net proceeds from this offering will be allocated toward working capital and general corporate purposes, specifically supporting Lexaria's ongoing research and development initiatives. This funding comes at a critical time for the company as it continues to advance its innovative DehydraTECH drug delivery platform. The offering is being conducted under a previously filed shelf registration statement that was declared effective by the Securities and Exchange Commission on January 30, 2025, providing the company with strategic flexibility in timing its capital-raising activities.

Lexaria's DehydraTECH technology platform represents a significant advancement in drug delivery systems, having demonstrated capabilities in improving bio-absorption and potentially reducing side effects of various medications. The platform's ability to enhance how drugs are absorbed by the body could lead to more effective treatments with lower dosages required. With 48 patents already granted worldwide and additional patents pending, Lexaria has established a strong intellectual property foundation for its technology.

This stock offering represents a strategic financial move for Lexaria, enabling the company to maintain its research momentum and pursue further technological developments in drug delivery solutions. The funding will support continued validation and optimization of the DehydraTECH platform across multiple therapeutic areas. The company's approach to capital raising through registered direct offerings provides efficient access to funding while minimizing market disruption, allowing management to focus on technological advancement rather than continuous fundraising activities.